Research & Development

Dr. Stanislaw R. Burzynski commenced his cancer research in 1967 focusing on the isolation of various biochemicals produced by the human body as part of the body’s possible defense against cancer. In the course of his research, Dr. Burzynski identified certain peptides, amino acid derivatives and organic acids in these biochemicals which appear to inhibit the growth of cancer cells. Dr. Burzynski named these derivatives antineoplastons.

Antineoplastons are found in the body fluids of humans and in foods, and initially were isolated by Dr. Burzynski from normal human blood and urine. Dr. Burzynski believes these substances counteract the development of cancerous growth through a biochemical process which does not inhibit the growth of normal tissues. All of the Phase II clinical trials currently sponsored by BRI involve the use of two formulations of synthetic ANP known as A10 and AS2-1 injections. BRI is also conducting laboratory research involving new generations of Antineoplastons A10 and AS2-1.